Objective  To analyze the occurrence regularities and clinical characteristics of the adverse reactions induced by olaparib, and provide a reference for rational drug use in clinical practice.

Methods  The case reports and case analyses of the adverse reactions induced by olaparib were retrieved from databases of CNKI, Wanfang Data, VIP, PubMed, Web of Science, Embase, and conduct statistical analysis on the basic information of patients, the use of drugs, the induction time of adverse reactions, clinical manifestations, treatment, and outcomes.

Results  A total of 20 case reports of adverse reactions to olaparib were collected, involving 23 patients and 25 adverse reactions, including 6 males and 17 females. The majority of patients were over 50 years old (20 cases, 86.96%), with an average age of (61.60±9.52) years. The main underlying disease was ovarian cancer (14 cases, 60.87%). The occurrence time of adverse reactions is relatively evenly distributed in different periods, with a higher probability of occurring within 180 days (20 cases, 80.00%). Adverse reactions mainly involved the blood system (28.00%), respiratory system (24.00%), and skin system (24.00%). Three patients recovered after discontinuing the medication, two patients recovered after reducing the dosage, and 11 patients recovered after discontinuing the medication and receiving symptomatic treatment. One patient died after discontinuing medication and receiving symptomatic treatment, while four patients died before discontinuing medication. Two patients did not mention any improvement.

Conclusion  Adverse reactions related to olaparib should be highly valued, and medication monitoring should be strengthened to reduce or stop administration promptly after adverse reactions occur, to reduce the risks of clinical medication.

1.Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic[J]. Science, 2017, 355(6330): 1152-1158. DOI: 10.1126/science.aam7344.

2.Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase[J]. Nature, 2005, 434(7035): 913-917. DOI: 10.1038/nature03443.

3.杨振宇, 李永红, 韩辉. 美国国立综合癌症网络临床实践指南: 前列腺癌(2023.V4)更新解读[J]. 临床外科杂志, 2024, 32(1): 55-57. [Yang ZY, Li YH, Han H. National comprehensive cancer network clinical practice guidelines: updated interpretation of prostate cancer (2023. V4)[J]. Journal of Clinical Surgery, 2024, 32(1): 55-57.] DOI: 10.3969/j.issn.1005-6483.2024.01.015.

4.苏怡, 杨国旺, 杨雯靖. 从价值医疗视角探讨晚期卵巢癌多腺苷二磷酸核糖聚合酶抑制剂维持治疗的用药选择[J]. 中国医院用药评价与分析, 2023, 23(8): 897-900, 907. [Su Y, Yang GW, Yang JW. Exploring medication selection for maintenance therapy of advanced ovarian cancer with poly (adenosine diphosphate ribose) polymerase inhibitors from the perspective of value medicine[J]. Evaluation and Analysis of Medication Use in Chinese Hospitals, 2023, 23(8): 897-900, 907.] DOI: 10.14009/j.issn.1672-2124.2023.08.001.

5.孔北华, 刘继红, 黄鹤, 等. 卵巢癌PARP抑制剂临床应用指南（2022版）[J]. 肿瘤综合治疗电子杂志, 2022, 8(3): 64-77. [Kong BH, Liu JH, Huang H, et al. Clinical application guidelines for PARP inhibitors in ovarian cancer (2022 Edition)[J]. Electronic Journal of Comprehensive Cancer Treatment, 2022, 8(3): 64-77.] DOI: 10.12151/JMCM.2022.03-07.

6.Naranjo C, Busto U, Sellers E, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.

7.Ma LL, Wang YY, Yang ZH, et al. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?[J]. Mil Med Res, 2020, 7(1): 7. DOI: 10.1186/s40779-020-00238-8.

8.李柄辉, 訾豪, 李路遥, 等. 医学领域一次研究和二次研究的方法学质量（偏倚风险）评价工具[J]. 医学新知, 2021, 31(1): 51-58. [Li BH, Zi H, Li LY, et al. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?[J]. New Medicine, 2021, 31(1): 51-58.] DOI: 10.12173/j.issn.1004-5511.2021.01.07.

9.姚海荣, 刘世凯. 奥拉帕利相关骨髓增生异常综合征[J]. 药物不良反应杂志, 2023, 25(11): 702-704. [Yao HR, Liu SK. Myelodysplastic syndrome associated with olaparib[J]. Adverse Drug Reactions Journal, 2023, 25(11): 702-704.] DOI: 10.3760/cma.j.cn114015-20221103-01023.

10.王祺茹, 左丽, 杜琼, 等. 1例奥拉帕利致Ⅳ度骨髓抑制患者的药学监护[J]. 中国药物警戒, 2023, 20(10): 1176-1180. [Wang QR, Zuo L, Du Q, et al. Pharmaceutical monitoring of a patient with grade IV bone marrow suppression induced by olaparib[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1176-1180.] DOI: 10.19803/j.1672-8629.20230166.

11.司倩, 毛新奇, 李文杰, 等. 临床药师参与1例前列腺癌患者应用奥拉帕利致间质性肺炎伴发热的治疗实践[J]. 中国合理用药探索, 2024, 21(3): 50-56. [Si Q, Mao XQ, Li WJ, et al. Clinical pharmacist participated in the treatment practice of a prostate cancer patient with Olaparib induced interstitial pneumonia accompanied by fever[J]. China Rational Drug Use, 2024, 21(3): 50-56.] DOI: 10.3969/j.issn.2096-3327.2024.03.009.

12.袁梦, 杨春艳, 武元竹, 等. 奥拉帕利致免疫性血小板减少症 [J]. 药物不良反应杂志, 2022, 24(10): 549-551. [Yuan M, Yang CY, Wu YZ, et al. Olaparib induced immune thrombocytopenia[J]. Adverse Drug Reactions Journal, 2022, 24(10): 549-551.] DOI: 10.3760/cma.j.cn114015-20220215 -00124.

13.孙红玲. 奥拉帕利致嗜酸粒细胞增多性肺炎[J]. 药物不良反应杂志, 2024, 26(1): 23-55. [Sun HL. Olaparib-induced eosinophilic pneumonia[J]. Adverse Drug Reactions Journal, 2024, 26(1): 23-55.] DOI: 10.3760/cma.j.cn114015-20230727-00559.

14.王燕婷, 李一帆, 杨珺, 等. 1例铂敏感复发卵巢癌患者服用奥拉帕利致血小板减少症的药学监护[J]. 中国药学杂志, 2021, 56(20): 1659-1663. [Wang YT, Li YF, Yang J, et al. Pharmaceutical care for olaparib-induced thrombocytopenia in a platinum-sensitive recurrent ovarian cancer patient[J]. Chinese Pharmaceutical Journal, 2021, 56(20): 1659-1663.] DOI: 10.11669/cpj.2021.20.007.

15.Ishimoto H, Sakamoto N, Kido T, et al. Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature[J]. BMC Pulm Med. 2023, 23(1): 289. DOI: 10.1186/s12890-023-02569-3.

16.Tufoni M, Serena Ricci C, Zaccherini G. A case of immune-mediated liver injury induced by Olaparib[J]. Hepatology, 2018, 68(5): 2039-2041. DOI: 10.1002/hep.30119.

17.Zhu K, Drew Y, Jayakumar S. Challenges in PARP inhibitor therapy: a case of olaparib-induced liver injury and successful rechallenge with Niraparib[J]. Gynecol Oncol Rep, 2024, 54: 101439. DOI: 10.1016/j.gore.2024.101439.

18.Alshelleh M, Park J, John V, et al. Olaparib-induced immune-mediated liver injury[J]. ACG Case Rep J, 2022, 9(1): e00735. DOI: 10.14309/crj.0000000000000735.

19.Kobak S. Olaparib-related seronegative inflammatory arthritis: fırst report in the literature[J]. Scand J Rheumatol, 2021, 50(1): 74-75. DOI: 10.1080/03009742.2020.1732462.

20.Wheelden M, Cream L, Sivik J, et al. A novel adverse event associated with olaparib therapy in a patient with metastatic breast cancer[J]. Case Rep Oncol Med, 2018, 2018(1): 9529821. DOI: 10.1155/2018/9529821.

21.Clark A, Weissman AS, Crowson AN, et al. Olaparib-induced pseudoporphyria in a patient with ovarian cancer[J]. JAAD Case Rep, 2023, 39: 58-60. DOI: 10.1016/j.jdcr.2023.07.011.

22.Kaitsumaru M, Shiota M, Takamatsu D, et al. Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report[J]. Int Canc Conf J, 2023, 12(2): 131-136. DOI: 10.1007/s13691-022-00592-5.

23.Maiko F, Ken S, Satoshi Y, et al. Olaparib-induced cutaneous vasculitis in a patient with recurrent ovarian cancer[J]. Eur J Dermatol, 2022, 32(5): 655-656. DOI: 10.1684/ejd.2022.4343.

24.Gou R, Horikawa N, Kosaka K. Olaparib-induced cutaneous side effects in a patient with recurrent ovarian cancer[J]. BMJ Case Rep, 2022, 15(4): e249177. DOI: 10.1136/bcr-2022-249177.

25.da Costa REAR, Valença RJV. A case of hand-foot syndrome with olaparib[J]. Pan Afr Med J, 2022, 43: 216. DOI: 10.11604/pamj.2022.43.216.38384.

26.Shammo JM, Usha L, Richardson KJ, et al. Olaparib-induced severe folate deficiency in a patient with advanced ovarian cancer[J]. J Oncol Pract，2019, 15(7): 405-407. DOI: 10.1200/JOP.18.00705.

27.Sekine M, Terui H, Fujimura T, et al. Olaparib-induced purpuric drug eruption in a patient with castration-resistant prostate cancer[J]. Case Rep Oncol, 2023, 16(1): 419-421. DOI: 10.1159/000530981.

28.Assaf I, Mans L, Sakr R, et al. Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance olaparib: two case reports and review of the literature[J]. Eur J Cancer, 2021, 157: 63-67. DOI: 10.1016/j.ejca.2021.07.042.

29.Roett MA, Evans P. Ovarian cancer: an overview[J]. Am Fam Physician, 2009, 80(6): 609-616. https://pubmed.ncbi.nlm.nih.gov/19817326/.

30.Rolfo C, de Vos-Geelen J, Isambert N, et al. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and renal impairment[J]. Clin Pharmacokinet，2019, 58(9): 1165-1174. DOI: 10.1007/s40262-019-00754-4.

31.Friedlander M, Lee YC, Tew WP. Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data[J]. Am Soc Clin Oncol Educ Book, 2023, 43: e390876. DOI: 10.1200/EDBK_390876.

32.Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.

33.Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation[J]. J Clin Oncol, 2015, 33(3): 244-250. DOI: 10.1200/JCO.2014.56.2728.

34.Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(9): 1274-1284. DOI: 10.1016/S1470-2045(17)30469-2.

35.Hopkins TA, Ainsworth WB, Ellis PA, et al. PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow[J]. Mol Cancer Res, 2019, 17(2): 409-419. DOI: 10.1158/1541-7786.MCR-18-0138.

36.de Botton S, Sabri S, Daugas E, et al. Platelet formation is the consequence of caspase activation within megakaryocytes[J]. Blood, 2002, 100(4): 1310-1317.DOI: 10.1182/blood-2002-03 -0686.

37.中国抗癌协会妇科肿瘤专业委员会. PARP抑制剂不良反应管理的中国专家共识（2021年版）[J]. 中国实用妇科与产科杂志, 2021, 37(11): 1119-1130. DOI: 10.19538/j.fk2021110111.

38.中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会. 中国肿瘤药物相关血小板减少诊疗专家共识（2023版）[J]. 中华医学杂志, 2023, 103(33): 2579-2590. [Chinese Anti Cancer Association Clinical Chemotherapy Professional Committee, Chinese Anti Cancer Association Tumor Support Treatment Professional Committee. Expert consensus on diagnosis and treatment of thrombocytopenia related to cancer drugs in China (2023 Edition)[J]. Chinese Journal of Medicine, 2023, 103(33): 2579-2590.] DOI: 10.3760/cma.j.cn112137-20230409-00575.

39.Roubaud G, Özgüroğlu M, Penel N, et al. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: further analyses from the PROfound study[J]. Eur J Cancer, 2022, 170: 73-84. DOI: 10.1016/j.ejca.2022.04.016.

40.Ma Z, Sun X, Zhao Z, et al. Risk of pneumonitis in cancer patients treated with PARP inhibitors: a Meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database[J]. Gynecol Oncol, 2021, 162(2): 496-505. DOI: 10.1016/j.ygyno.2021.05.012.

41.Zhang Y, Huang W, Zheng Z, et al. Cigarette smoke-inactivated SIRT1 promotes autophagy-dependent senescence of alveolar epithelial type 2 cells to induce pulmonary fibrosis[J]. Free Radic Biol Med, 2021, 166: 116-127. DOI: 10.1016/j.freeradbiomed.2021.02.013.

42.王威威, 张羽瑶, 王家玉, 等. 临床药师参与1例卡培他滨致晚期乳腺癌患者手足综合征治疗实践[J]. 中国药业, 2023, 32(22): 143-147. [Wang WW, Zhang YY, Wang JY, et al. Clinical pharmacist participated in the treatment of hand foot syndrome in a patient with advanced breast cancer caused by capecitabine[J]. China Pharmaceuticals, 2023, 32(22): 143-147.] DOI: 10.3969/j.issn.1006-4931.2023.22.033.

43.Leung AKC, Leong KF, Lam JM. Erythema nodosum[J]. World J Pediatr, 2018, 14(6): 548-554. DOI: 10.1007/s12519-018-0191-1.

44.Mert A, Kumbasar H, Ozaras R, et al. Erythema nodosum: an evaluation of 100 cases[J]. Clin Exp Rheumatol, 2007, 25(4): 563-570. https://pubmed.ncbi.nlm.nih.gov/17888212/.

45.Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10106): 1949-1961. DOI: 10.1016/S0140-6736(17)32440-6.

46.Mateos-Pujante A, Jiménez MC, Andreu I. Evaluation of phototoxicity induced by the anticancer drug rucaparib[J]. Sci Rep, 2022, 12(1): 3434. DOI: 10.1038/s41598-022-07319-9.

47.Mukhopadhyay P, Horváth B, Rajesh M, et al. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis[J]. J Hepatol，2017, 66(3): 589-600. DOI: 10.1016/j.jhep.2016.10.023.

48.Alshelleh M, Park J, John V, et al. Olaparib-induced immune-mediated liver injury[J]. ACG Case Rep J, 2022, 9(1): e00735. DOI: 10.14309/crj.0000000000000735.

49.Song Y, Barry WT, Seah DS, et al. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers[J]. Cancer, 2020, 126(2): 271-280. DOI: 10.1002/cncr.32540.

50.Miesel R, Kurpisz M, Kröger H. Modulation of inflammatory arthritis by inhibition of poly(ADP ribose) polymerase[J]. Inflammation, 1995, 19(3): 379-387. DOI: 10.1007/BF01534394.